JP7271430B2 - 抗ｘｉ因子抗体 - Google Patents

抗ｘｉ因子抗体 Download PDF

Info

Publication number
JP7271430B2
JP7271430B2 JP2019543277A JP2019543277A JP7271430B2 JP 7271430 B2 JP7271430 B2 JP 7271430B2 JP 2019543277 A JP2019543277 A JP 2019543277A JP 2019543277 A JP2019543277 A JP 2019543277A JP 7271430 B2 JP7271430 B2 JP 7271430B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
fxi
fxia
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507578A5 (enExample
JP2020507578A (ja
Inventor
ワン，ウェンイ
ユ，クアン
リウ，シャオウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Benemae Pharmaceutical Corp
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Publication of JP2020507578A publication Critical patent/JP2020507578A/ja
Publication of JP2020507578A5 publication Critical patent/JP2020507578A5/ja
Application granted granted Critical
Publication of JP7271430B2 publication Critical patent/JP7271430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019543277A 2017-02-10 2017-12-29 抗ｘｉ因子抗体 Active JP7271430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体
CN201710073984.X 2017-02-10
PCT/CN2017/119856 WO2018145533A1 (zh) 2017-02-10 2017-12-29 抗凝血因子xi抗体

Publications (3)

Publication Number Publication Date
JP2020507578A JP2020507578A (ja) 2020-03-12
JP2020507578A5 JP2020507578A5 (enExample) 2021-02-12
JP7271430B2 true JP7271430B2 (ja) 2023-05-11

Family

ID=63107934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543277A Active JP7271430B2 (ja) 2017-02-10 2017-12-29 抗ｘｉ因子抗体

Country Status (9)

Country Link
EP (1) EP3581587B1 (enExample)
JP (1) JP7271430B2 (enExample)
KR (1) KR102690437B1 (enExample)
CN (1) CN108409863B (enExample)
AU (2) AU2017397778B2 (enExample)
BR (1) BR112019016300A2 (enExample)
CA (1) CA3054322A1 (enExample)
MX (1) MX2019009500A (enExample)
WO (1) WO2018145533A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
EP3914624A4 (en) * 2019-01-21 2022-10-19 Aronora, Inc. NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES
CN113474374B (zh) * 2019-04-16 2025-05-02 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN110498839A (zh) * 2019-09-19 2019-11-26 河南省农业科学院 氟罗沙星单链抗体关键多肽序列及应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TWI882142B (zh) * 2020-07-02 2025-05-01 大陸商北京拓界生物醫藥科技有限公司 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981754B2 (ja) * 1990-02-02 1999-11-22 第一化学薬品株式会社 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体
KR100925348B1 (ko) * 2001-06-12 2009-11-09 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항-혈액 응고 인자 ⅷ 항체
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (en) * 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Identification of a Factor IX Binding Site on the Third Apple Domain of Activated Factor XI，THE JOURNAL OF BIOLOGICAL CHEMISTRY，1996年，Vol. 271, No. 46，29023-29028
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI，BLOOD，2009年，VOLUME 113, NUMBER 4，936-944

Also Published As

Publication number Publication date
KR20190116990A (ko) 2019-10-15
MX2019009500A (es) 2020-01-30
EP3581587A1 (en) 2019-12-18
KR102690437B1 (ko) 2024-07-30
AU2025203303A1 (en) 2025-05-29
EP3581587A4 (en) 2021-03-31
CN108409863A (zh) 2018-08-17
AU2017397778A1 (en) 2019-10-03
WO2018145533A1 (zh) 2018-08-16
RU2019128423A3 (enExample) 2021-03-19
EP3581587B1 (en) 2025-02-05
CA3054322A1 (en) 2018-08-16
CN108409863B (zh) 2023-09-26
JP2020507578A (ja) 2020-03-12
AU2017397778B2 (en) 2025-03-06
BR112019016300A2 (pt) 2020-06-16
RU2019128423A (ru) 2021-03-10

Similar Documents

Publication Publication Date Title
JP7271430B2 (ja) 抗ｘｉ因子抗体
JP6830533B2 (ja) 抗ｉｌ−３３抗体およびその使用
JP2022046656A (ja) 抗凝固因子ｘｉ抗体
JP7022081B2 (ja) 抗凝固因子ｘｉ抗体
BRPI0924058B1 (pt) Anticorpos monoclonais, seus usos, bem como composição farmacêutica
CN113227150B (zh) 抗凝血因子xi抗体
AU2018214222A1 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
JP2014515743A (ja) Ｔｇｆ−アルファおよびエピレグリンに結合する抗体
US11958911B2 (en) Anti-coagulation factor XI antibody
RU2800719C2 (ru) Антитела к фактору xi
HK40010556A (en) Anti-coagulation factor xi antibody
HK40075243A (en) Anticoagulant factor xi antibodies
HK40075244A (en) Anticoagulant factor xi antibodies
HK40075244B (zh) 抗凝血因子xi抗体
HK40075243B (zh) 抗凝血因子xi抗体
HK40057273A (en) Anti-factor xi antibodies
HK40057273B (zh) 抗凝血因子xi抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230426

R150 Certificate of patent or registration of utility model

Ref document number: 7271430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150